• The integrin Mac-1 I-domain interaction with platelet receptor GPIba has been mapped by NMR.
Introduction
The integrin receptor macrophage-1 antigen (Mac-1, also known as CR3, integrin a M b 2 , or CD11b/CD18) is expressed on the surface of myeloid leukocytes and mediates numerous responses of these cells critical to innate immunity. 1 The Mac-1 receptor contributes to the recruitment, firm adhesion, and transendothelial migration of leukocytes at sites of vascular injury and facilitates tissue inflammation. 2 Biochemical and cellbased studies have characterized the interactions of the Mac-1 integrin with diverse ligands, including plasma protein fibrinogen, 3 complement protein fragment iC3b, 4 high-molecular-weight kininogen , 5 and the cell-surface receptors platelet glycoprotein Iba (GPIba) 2 and intercellular adhesion molecule 1 (ICAM-1). 6 The Mac-1 integrin exists in an inactive conformation and, when activated by a variety of stimuli, undergoes a structural change to an active form capable of binding to ligands with high affinity. 7, 8 Concurrently, allosteric changes occur on ligand binding that result in "outside-in" cell signaling.
Mac-1-deficient mice show delayed thrombosis, but largely unimpaired hemostasis. 10 Blocking the Mac-1:GP1ba interaction prevents neutrophil extracellular trap formation, 11 and an antibody targeting Mac-1 was shown to block inflammation. 12 Inhibiting the Mac-1 I-domain with the small molecule allosteric regulator leukaderin-1 has demonstrated efficacy in animal models of inflammatory disease. 13, 14 For the majority of Mac-1 interactions described, the inserted aM-subunit, or "I-domain," is the principal ligand-binding domain. The Mac-1 I-domain contains a Mg 21 binding site on its surface at the top of the b sheet called the metal ion-dependant adhesion site (MIDAS), which is capable of accepting the side chain of an acidic residue (aspartate or glutamate) from coordinating ligands. 1, 7 A crystal structure has defined the interaction between Mac-1 and iC3b, 4 but the complex between Mac-1 and GPIba and the principal ligand fibrinogen 3 are poorly understood at the molecular level. Here, nuclear magnetic resonance (NMR) assignment of the mouse Mac-1 I-domain, together with X-ray structural analysis of both the mouse GP1baΝ and Mac-1 I-domain, has enabled us to map the binding surface and model the interaction site for the GP1ba leucine-rich repeat (LRR) N-terminal domain (GP1baN) with the MIDAS face of Mac-1.
Materials and methods

Protein expression, purification, and characterization
A complementary DNA fragment encoding mouse GP1baN residue E1 to T266 (mature protein sequence numbering) was cloned into the pMT-puro vector for expression using the DES system (Invitrogen). At the N terminus, the signal sequence corresponds to a Drosophila homolog of the immunoglobin binding chaperone protein secretion signal, and a polyhistidine tag sequence TRTGHHHHHH was added at the C terminus. Site-specific mutations H218A and E222A were introduced using the QuikChange method (Stratagene) and confirmed by DNA sequencing. The mouse amino acid sequence numbering is defined by alignment with the mature human GP1ba sequence, such that H218 corresponds to H234 in the UniProt numbering of entry GP1BA_MOUSE, which includes the signal sequence. Drosophila S2 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum at 28°C and transfection was performed in each case using calcium phosphate. Cells were grown for an additional 48 hours before selection with puromycin to establish stable cell lines. Serum-free Express Five (Invitrogen) insect culture media was collected containing secreted proteins. Initial capture of the crude product was performed using Ni-sepharose affinity chromatography, followed by gel filtration and ion exchange chromatography (supplemental Figure 1) . Protein identity and successful removal of the signal peptide was confirmed by trypsin digest mass spectrometry, analyzed using the Mascot Database (ProteinID, University of York) shown in supplemental Figures 1 and 2 .
The mouse Mac-1 I-domain gene fragment (P129 to A318; mature protein sequence numbering) was cloned into the pGEX-4T-1 vector, for expression as an N-terminal GST-fusion using Escherichia coli. All mutants were produced using Q5 site-directed mutagenesis. XL1-Blue and BL21 cells were transformed using calcium chloride for storage and expression, respectively. BL21 cells were grown in LB media (for surface plasmon resonance [SPR] and mass spectrometry) or M9 minimal media (for NMR spectroscopy) supplemented with 15 N ammonium chloride and/or 13 C glucose as required for isotope labeling. GST-affinity chromatography and incubation with thrombin resulted in the separation of the tag (residual Gly-Ser remains at the N terminus) and further purification using cationic exchange chromatography. Mass spectrometry, gel filtration studies, NMR line width analysis, and diffusion measurements indicate that the recombinant Mac-1 I-domain is monomeric in solution (supplemental Figures 3 and 4) .
NMR spectroscopy
NMR data were recorded at 25°C on a Bruker 800 MHz Avance III spectrometer with a QCI cryoprobe using Topspin 3.1 software. Backbone resonances ( 13 C/ 15 N) were assigned using HNCO, HN(Ca)CO, CbCaNH, and CbCa(CO)NH experiments. Backbone assignment (.146/182 residues) was facilitated by a number of locally perturbing single-point mutations (to Ala/Gly) and through selective unlabeling experiments (Glu and Lys, in particular). 15 N-TROSY 2D spectra were collected in titration experiments at a Mac-1 concentration of 120 mM in 25 mM potassium phosphate buffer (pH 7.0), 25 mM NaCl, 5% D 2 O, and 0.02% NaN 3 using 1.5 equivalents of MgCl 2 to ensure metal complexation.
15 N-TROSY spectra were collected at 0.2 molar ratio intervals up to a 2:1 excess of GPIbaN. Chemical shift perturbations (CSPs) were calculated using a weighting of 1 H and 15 N shifts according to:
For structural modeling, the standard deviation (SD) from the mean CSP was calculated and mean 1 SD and mean 1 2 3 SD used for surface mapping.
Quantitation of Mac-1 I-domain ligand binding
SPR was performed using a BIAcore 3000 (GE Healthcare). Ligands of recombinant mouse GPIbaN, GPIbaN variants H218A and E222A, and fibrinogen (s) were amine-coupled to a CM5 sensor chip (GE Healthcare); a reference cell was prepared by blank aminecoupling. Recombinant Mac-1 I-domain wild-type and T209A variant samples at protein concentrations ranging from 3.125 mM to 200 mM, in running buffer (10 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid, pH 7.4, 140 mM NaCl, 1 mM MgCl 2 ) were injected at a flow rate of 50 mL/min. Kinetic studies of the Mac-1 I-domain wild-type and T209A constructs were conducted as a dilution series, in the presence and absence of Mg 21 against the immobilized GPIbaN. Each of the series contains a minimum of 10 concentrations (11.25-200 mM) and was repeated a minimum of 2 times. The Mg 21 ion dependence of the GPIbaN interaction was tested against a wild-type Mac-1 I-domain concentration series (6-100 mM) in which the running buffer contained 5 mM EDTA to sequester metal ions. Binding to the immobilized GPIbaN was also evaluated using a dilution series of the antibody Xia.B2 (emfret ANALYTICS) with protein concentration of 3 to 50 nM. The CM5 chip was regenerated with 2 M NaCl after each experiment. Binding curves were generated by subtracting the appropriate controls and the resulting curves were analyzed using BIAevaluation software or a steady-state equilibrium approach using a Hill plot generated with Prism 6 (GraphPad Software Inc.).
2-propanol; 1,4-butanediol; 1,3-propanediol, 0.1 M imidazole; MES monohydrate (acid) pH 6.5, 20% v/v ethylene glycol; and 10% w/v PEG 8000. Crystals of the mouse Mac-1 I-domain (6 mg/mL) grew in the JCSG1 screen condition D7, 0.2 M lithium sulfate, 0.1 M tris(hydroxymethyl)aminomethane, pH 8.5, 40% PEG 400. Crystals were cryocooled in liquid nitrogen and X-ray diffraction data were collected using the ID30B beamline at the ESRF (GP1baN) and Diamond beamline I24 (Mac-1 I-domain). Data were processed with XDS and molecular replacement was performed with PHASER using a human GP1baN 15 and Mac-1 I-domain structure 7 (Table 1) . Partial model building was performed using BUCCANEER and completed manually using COOT and refined with REFMAC5 (deposited PDB code: 6EJX).
Molecular docking calculations
Three-dimensional models of the Mac-1 I:GPIbaN docked complex structures were calculated using HADDOCK 16 with template Mac-1 I-domain (PDB code: 1IDO) and GPIbaN (PDB code: 1M0Z) crystal structures used. Active residues were defined based on the Mac-1 I-domain NMR titration experiments: E244, G143, and N147 plus the MIDAS Mg 21 ion. Active residues for GPIbaN were D222 and R218.
Results
NMR assignment and structural analysis of the Mac-1 I-domain
A bacterially expressed mouse Mac-1 I-domain construct (residues 129-318) was isotopically ( Figure 5 ). We also prepared and characterized 2 Mac-1 mutants, T209A and F302W, which have previously been reported as "inactive" (T209A) and "pseudo-open" (F302W) variants of the I-domain. 17, 18 The side chain of T209 coordinates directly with the Mg 21 ion only in the "open" conformation of the Mac-1 I-domain, 4, 7 and previous crystallographic studies have defined a large allosteric conformational shift between "open" and "closed" states, which links the switching of the coordination of the metal ion from D140 to T209 to a shift in the position of helix a7. 7, 19 T209 has also been shown to play a direct and critical role in Mac-1 ligand binding to ICAM-1 and iC3b. 6 The CD spectra of the mutants and wild-type Mac-1 are superimposable, showing no significant changes in protein secondary structure and folding (supplemental Figure 1B) . NMR of the 15 N-labeled mutant proteins confirms retention of the core structure; however, extensive perturbations across the MIDAS face are evident in both mutants (supplemental Figure 5 ).
NMR analysis of the Mac-1 I-domain interaction with GP1baN
Recombinant mouse GP1baN was expressed and purified from insect cells (supplemental Figures 1 and 2 ). NMR chemical shifts ( A significant number of fast-exchange CSPs are observed in response to ligand binding. However, a number of residues within the Mac-1 I-domain C-terminal region (helix a7) showed some evidence of signal broadening and peak distortion in the bound state. Statistically significant CSP effects are identified for 16 residues of the Mac-1 I-domain ( Figure 1 ) and enable us to identifying 2 welldefined binding patches. The first group of residues, which are in close proximity or intimately involved in MIDAS Mg 21 coordination, includes D140, S142, G143, I145, and D242 together with the adjacent solvent-exposed residues N147, K210, and E244. Residues D242, E244, and D273 cluster on the surface of the I-domain to form a negatively charged patch that is adjacent to the MIDAS. The second group of Mac-1 residues I265, R266, F275, G293, E294, H295, and V296 ( Figure 1D -E) are distal to the MIDAS and appear to be linked to it through conformational changes propagated away from the metal center.
Crystal structures of the mouse GP1baN and Mac-1 I-domain
We next determined the crystal structure of mouse Mac-1 I-domain to 2.5Å resolution. This revealed the mouse Mac-1 I-domain in an open conformation with the MIDAS metal ion coordinated by T209, S142, S144, and a glutamic acid residue (E314) ligand mimetic supplied by a crystal contact from the C-terminal helix (a7) of the Figure 2A ; supplemental Video 1). The C-terminal Mac-1 I-domain a-helix consists of the amino acid sequence 310-NQLQE-314, which resembles the sequence from the a-helix in the GPIbaN capping region spanning residues 218-HWLQE-222, and is equivalent structurally in terms of the a-helical disposition of the glutamic acid residue. Figure 2B shows that the a-helix sits in a groove on the surface of the Mac-1 I-domain packing against residues F246 and R208, forming multiple hydrogen bonded contacts between the sidechains of N310 and N306 and the sidechains of E244 and K277 on the MIDAS face. For comparison, crystal structures are available for the human Mac-1 I-domain as an open conformation in complex with ligand iC3b, 4 simvastatin, 20 and stabilized by a crystal contact. 7, 8 The mouse and the human Mac-1 I-domain crystal structures are superposed in Figure 2D , revealing the MIDAS metal ion coordinating acidic residue consistently occupies an identical position simultaneously bonding to both the metal ion and the hydroxyl of T209. Subtle differences occur across the MIDAS face with the introduction of K277 in the mouse Mac-1 forming a salt bridge to E244, replacing the K279-E244 salt bridge observed in the human structure ( Figure 2C ).
We then determined the crystal structure of the mouse GP1baN to 2.0Å resolution to examine the conformation of the LRR C-terminal capping a-helix, which is important for the interaction with Mac-1.
2
This structure reveals overall features of the LRR solenoid flanked by N-and C-terminal disulphide-bonded capping regions and R-loop, as observed previously for the human GP1baN structure. 21 The junction between the C-terminal capping region a-helix and the LRR solenoid forms an elongated pocket ( Figure 3A , dotted elliptical line). In a notable departure from the human sequence, Figure 3B -D reveals that the mouse GP1baN has the substitutions H218 and E222 that, by analogy with the human GP1baN structure, are also surface exposed ( Figure 3B) . A comparison of structures shows that mouse GP1baN H218 and E222 occur with the same disposition as human GP1baN R218 and D222, respectively, and a sequence alignment of this region reveals that charged residues at these positions are conserved across other mammalian species ( Figure 3C ).
Docking of the GPIbaN and Mac-1 I-domain 3-dimensional structures
Previous cell-based and biochemical studies identified residues 218 through 228 from GP1ba as the principal determinants of the Mac-1 interaction 2 encompassing the human GP1baN LRR C-terminal . For personal use only on May 9, 2019. by guest www.bloodadvances.org From capping a-helix, but did not specify whether a critical acidic residue was involved. Studies using a variety of techniques implicated Mac-1 as residing on the MIDAS face and residues T213 and R216 as being located away from the MIDAS face, but did not propose a role for the Mg 21 ion or an overall model for the complex with GP1baN.
10,22
We thus set out to investigate this by generating models of the Mac-1 I:GP1baN complex using the program HADDOCK. 16 Multiple crystal structures are available for the human Mac-1 I-domain in the open conformation 4, 7, 8, 18, 23 and human GP1baN domain, 15, 21, [24] [25] [26] and they were used as templates for docking.
Docking was performed using NMR distance restraints between the Mac-1 MIDAS Mg 21 ion and residues G143, N147, D242, and E244, which were identified as having significant CSP effects in the NMR titration experiments, together with GP1baN surfaceexposed residues R218, D222, and N223. 2 The top scoring structure and details of the interface are shown in Figure 4A . The Mac-1 I:GP1baN complex buries a surface area of 593Å 2 (calculated using PISA), and 2 key features that define the unique orientation are that GP1baN D222 coordinates to the Mac-1 MIDAS Mg 21 ion and GP1baN R218 forms bidentate salt bridges with Mac-1 residues D242 and E244 (supplemental Videos 2 and 3). As viewed down the central projection of the GP1baN capping a-helix, colored orange in Figure 4B , residues G143 and S144 of Mac-1 (lower left) hydrogen bond to the side chains of N221 and R217 of GP1ba, respectively. Flanking interactions also occur on the right of Figure 4B as R208 from Mac-1 forms hydrogen bonds to the side chains of N223 of GP1ba, and its own H195 main chain carbonyl. The Mac-1 I-domain F246 side chain inserts into an elongated hydrophobic pocket in the GP1baN LRR capping region defined by GP1ba residues F192, S194, Y215, and W219 ( Figure 4C ).
SPR analysis of the Mac-1 I:GPIbaN interaction
To further evaluate the contribution of amino acid side chains at the center of the proposed mouse Mac-1 I:GP1baN interface, we used site-directed mutagenesis coupled with SPR. To establish the assay, the SPR response was first observed with Mac-1 I-domain analyte and immobilized full-length fibrinogen, which has been characterized in detail from previous studies. 3 SPR analysis ( Figure 5A ) shows a high-affinity interaction with evidence of multiple binding modes; an estimated K d of 30 mM was derived from the equilibrium values of response units was consistent with previous reports. 3 A ligand surface of GPIbaN was generated through amine-coupling to a CM5 chip. To determine the integrity of the GPIbaN surface, a dilution series with the antibody Xia.B2 (emfret ANALYTICS) was conducted and analysis of sensorgrams resulted in a K d of 34 nM, consistent with the anticipated high affinity for an antibody-antigen interaction, confirming the immobilized GPIbaN is forming an active surface. Sensorgrams were recorded using wild-type Mac-1 I-domain as the analyte and high-quality SPR curves were obtained ( Figure 5B Figure 5B, bottom) , which was similarly the case with wild-type Mac-1 with EDTA in excess (5 mM) to remove the metal ion from the MIDAS (data not shown). These experiments demonstrate that the bound Mg 21 ion in the MIDAS is critical to the interaction and confirm that the observed distal CSP effects in the NMR titration data arise from allosteric effects propagated away from the MIDAS site, rather than to a second ligand-binding site. In contrast with GPIbaN, at least 1 of these binding interactions is still evident from the SPR analysis with full-length fibrinogen and Mac-1 T209A, although the overall binding affinity is greatly reduced (Figure 5A, bottom) . This is consistent with a primary binding site around the MIDAS surface, along with a second, low-affinity Mac-1 I-domain site. 3 We further tested the model of the Mac-1 I:GPIbaN complex by generating recombinant mouse GP1baN variants H218A and E222A, which were purified with a similar protocol and produced a similar yield to the wild-type protein (supplemental Figure 1A) . SPR studies using the immobilized GPIbaN mutants with the wild-type Mac-1 I-domain as the analyte revealed that GP1baN H218A and E222A substitutions led to a loss of SPR response, preventing the sensorgrams from being fitted using either kinetic or equilibrium binding models, indicating significant impairment of the interaction with the Mac-1 I-domain ( Figure 5C ).
Discussion
Interactions among innate immune cells, platelets, and plasma proteins have been implicated in pathways leading to thrombosis, 10, [27] [28] [29] and yet very few of these protein interactions have been fully described. To the best of our knowledge, we provide the first detailed description of the complex formed between the leukocyte integrin Mac-1 I-domain and the platelet receptor GPIbaN using a combination of NMR, crystallography, site-directed mutagenesis, and SPR binding studies. We establish the principle that the Mac-1 I-domain in the open conformation has a groove on the surface formed by the extended sidechains of F246 and R208 and other residues that can accommodate an a-helix appropriately positioned by an acidic side chain coordinating the MIDAS metal ion and the side chain hydroxyl of T209. We show that the GPIbaN receptor LRR C-terminal capping a-helix uses a key acidic residue (D222 in the human; E222 in the mouse ortholog) to coordinate to the vacant site in the metal ion coordination shell of the Mac-1 MIDAS Mg 21 ion.
The presence of the integrin-binding acidic residue at the end of an a-helix in GPIbaN is reminiscent of the crystal structure of the Mac-1 I-domain complex with iC3b, whereby the integrin MIDAS metal ion binding residue D1247 of iC3b is also placed at the end of an . For personal use only on May 9, 2019. by guest www.bloodadvances.org From a-helix. 4 A comparison of the Mac-1 I:iC3b and Mac-1 I:GPIbaN complexes reveals the MIDAS-coordinating a-helix is oriented differently (90°rotation) in each ligand relative to the Mac-1 I-domain surface. In addition, unlike GP1baN, iC3b does not use the negatively charged patch (E244) on the surface of the Mac-1 I-domain for binding, but in common with GP1baN it does use Mac-1 I-domain residue R208. 4 These interactions suggest that the ability of the Mac-1 I-domain to bind a host of specific ligands involves a common binding surface and fits with the previously proposed mosaic model of Mac-1 ligand binding. 30 By contrast, GPIbaN uses 3 spatially separated regions of the receptor to bind the structurally distinct ligands of the von Willebrand factor A1 domain 24, 26 (GPIba LRRs and R-loop), thrombin 25, 31 (GPIba anionic region), and Mac-1 (GPIba C-terminal LRR cap).
The Mac-1 MIDAS interaction with an acidic residue from an a-helix of the ligand contrasts to the closely related integrin leukocyte function associated antigen-1 (LFA-1), which exploits a glutamate residue located within a b strand of the ligand ICAM-1 32 to bind the LFA-1 MIDAS a-subunit I-domain. A variety of studies have defined a large allosteric conformational shift between open and closed states of the leukocyte integrins Mac-1 and LFA-1 linked to the disposition of a-I-domain helix a7 and switching of the coordination shell within the MIDAS between D140 and T209. 7, 9 NMR studies have been previously reported for the related LFA-1 I-domain, 33 but to date no NMR characterization has been applied to Mac-1. LFA-1 does not bind GPIbaN, and a series of LFA-1/Mac-1 chimeras have been used previously to localize the binding site for GPIbaN within the Mac-1 I-domain to specific residues. Many of these are consistent with the Mac-1:GP1baN interface shown in Figure 4 , 22 but residues T213 and R216 are not part of the MIDAS face of the Mac-1 I-domain structure. 10 The crystal structures of Mac-1 I-domain reveals the T213 side chain hydroxyl group is buried and hydrogen bonded by contact with the D248 side chain in both the open and closed conformation and thus is not present on the surface to interact with a ligand. Mac-1 residues T213 and R216 are very close to key MIDAS face residues R208 and F246 and thus may affect binding indirectly, or, alternatively, R216 could form part of a second binding site for GP1baN.
Overall, we believe this is the first detailed description of the interface formed between an integrin receptor and an LRR protein revealing an elongated pocket in the GPIbaN LRR C-terminal capping region, which is key to the interaction. The Mac-1 integrin is not the only integrin to engage multiple ligands and, interestingly, the more distantly related integrin a 2 b 1 binds to collagen 19 as the principal ligand and has a well-characterized additional interaction with the LRR C-terminal capping region of the matrix protein chondroadherin. 34 The binding site for the a 2 b 1 integrin is localized to the chondroadherin sequence of residues LRRWLEAK, 34 which resembles the FRRWLQDN sequence we report for GPIba. Chondroadherin crystal structures reveal the LRRWLEAK sequence has an acidic residue that is surface exposed within the a-helix of the LRR capping region in a similar manner to GPIbaN. Previous authors also have speculated that the groove adjacent to the a-helix could be used by the integrin as described here. 35, 36 This structural scaffold describing an integrin-LRR protein interaction will facilitate the development of agents targeting Mac-1 or GPIbaN for the modulation of thrombotic and inflammatory disorders. RU, response unit.
14 MAY 2019 x VOLUME 3, NUMBER 
